Want to see CLDX full AI Analyst Report?
CLDX Stock Chart & Stats
$34.55
-$0.90(-3.26%)
At close: 4:00 PM EST
$34.55
-$0.90(-3.26%)
Day’s Range― - ―
52-Week Range$19.72 - $40.30
Previous CloseN/A
Volume733.18K
Average Volume (3M)1.14M
Market Cap
$3.01B
Enterprise Value$1.67K
Total Cash (Recent Filing)$451.46M
Total Debt (Recent Filing)$1.91M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Aug 06, 2026EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.27
Shares Outstanding78,492,070
10 Day Avg. Volume801,503
30 Day Avg. Volume1,140,233
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)3.43
Price to Sales (P/S)1204.09
P/FCF Ratio-8.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$51.10Price Target Upside47.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-4.35
Revenue Forecast (FY)$2.39M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt-to-equity (~0.4%) materially reduces refinancing and interest rate risk for a cash-burning biotech. This structural balance-sheet strength preserves optionality to fund trials, pursue partnerships, or bridge setbacks without immediate solvency stress, supporting multi‑month operations.
Focused Clinical PipelineA concentrated pipeline in antibody-based therapeutics for oncology and inflammatory/allergic disorders gives Celldex domain expertise and clear go-to-market pathways. Focused science increases the potential for durable competitive differentiation and strategic partnerships if clinical data validate targets.
Governance & Incentive FlexibilityShareholder approval of an expanded equity incentive plan and board continuity signals governance alignment and provides durable tools to attract/retain scientific and executive talent. Strong governance backing supports long-term program execution and continuity through multi‑phase trials.
Bears Say
High Cash BurnSustained operating and free cash flow deficits (roughly -$222M to -$224M TTM) create persistent funding needs. Over months this forces reliance on external financing or partnerships, raising dilution risk and potentially constraining program timelines if capital access tightens.
Declining Revenue BaseA small, volatile revenue base with a ~45% TTM decline undermines self-funding prospects. Without recurring product sales, the firm depends on milestone, collaboration, or capital-market funding, reducing resilience to clinical delays and making multi‑period planning more uncertain.
Deep Negative ProfitabilityExtremely negative margins and ROE reflect structural loss-making status tied to R&D intensity and no commercial revenues. Over time this erodes shareholder equity and limits reinvestment capacity absent new capital, elevating execution risk for late‑stage studies and commercialization.
Celldex News
CLDX FAQ
What was Celldex Therapeutics’s price range in the past 12 months?
Celldex Therapeutics lowest stock price was $19.72 and its highest was $40.30 in the past 12 months.
What is Celldex Therapeutics’s market cap?
Celldex Therapeutics’s market cap is $3.01B.
When is Celldex Therapeutics’s upcoming earnings report date?
Celldex Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 20 days.
How were Celldex Therapeutics’s earnings last quarter?
Celldex Therapeutics released its earnings results on May 07, 2026. The company reported -$1.18 earnings per share for the quarter, missing the consensus estimate of -$1.15 by -$0.03.
Is Celldex Therapeutics overvalued?
According to Wall Street analysts Celldex Therapeutics’s price is currently Undervalued.
Does Celldex Therapeutics pay dividends?
Celldex Therapeutics does not currently pay dividends.
What is Celldex Therapeutics’s EPS estimate?
Celldex Therapeutics’s EPS estimate is -1.06.
How many shares outstanding does Celldex Therapeutics have?
Celldex Therapeutics has 78,492,070 shares outstanding.
What happened to Celldex Therapeutics’s price movement after its last earnings report?
Celldex Therapeutics reported an EPS of -$1.18 in its last earnings report, missing expectations of -$1.15. Following the earnings report the stock price went up 1.951%.
Which hedge fund is a major shareholder of Celldex Therapeutics?
Currently, no hedge funds are holding shares in CLDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Celldex Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.10 (47.90% Upside)
$51.10 (47.90% Upside)
Blogger Sentiment
Bullish
CLDX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 83.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 8.4%
Last 30 Days ▲ 8.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.65%
12-Months-Change
Fundamentals
Return on Equity
-50.72%
Trailing 12-Months
Asset Growth
-30.86%
Trailing 12-Months
Company Description
Celldex Therapeutics
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
CLDX Stock 12 Month Forecast
Average Price Target
$51.10
▲(47.90% Upside)
Technical Analysis
Travere Therapeutics
―
Viridian Therapeutics
―
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Ownership Overview
0.30% Insiders
25.03% Mutual Funds
1.41% Other Institutional Investors
58.81% Public Companies and
Individual Investors